Hospitalized patients dying with SARS-CoV-2 infection-An analysis of patient characteristics and management in ICU and general ward of the LEOSS registry.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 08 10 2021
accepted: 08 07 2022
entrez: 29 7 2022
pubmed: 30 7 2022
medline: 3 8 2022
Statut: epublish

Résumé

COVID-19 is a severe disease with a high need for intensive care treatment and a high mortality rate in hospitalized patients. The objective of this study was to describe and compare the clinical characteristics and the management of patients dying with SARS-CoV-2 infection in the acute medical and intensive care setting. Descriptive analysis of dying patients enrolled in the Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS), a non-interventional cohort study, between March 18 and November 18, 2020. Symptoms, comorbidities and management of patients, including palliative care involvement, were compared between general ward and intensive care unit (ICU) by univariate analysis. 580/4310 (13%) SARS-CoV-2 infected patients died. Among 580 patients 67% were treated on ICU and 33% on a general ward. The spectrum of comorbidities and symptoms was broad with more comorbidities (≥ four comorbidities: 52% versus 25%) and a higher age distribution (>65 years: 98% versus 70%) in patients on the general ward. 69% of patients were in an at least complicated phase at diagnosis of the SARS-CoV-2 infection with a higher proportion of patients in a critical phase or dying the day of diagnosis treated on ICU (36% versus 11%). While most patients admitted to ICU came from home (71%), patients treated on the general ward came likewise from home and nursing home (44% respectively) and were more frequently on palliative care before admission (29% versus 7%). A palliative care team was involved in dying patients in 15%. Personal contacts were limited but more often documented in patients treated on ICU (68% versus 47%). Patients dying with SARS-CoV-2 infection suffer from high symptom burden and often deteriorate early with a demand for ICU treatment. Therefor a demand for palliative care expertise with early involvement seems to exist.

Sections du résumé

BACKGROUND
COVID-19 is a severe disease with a high need for intensive care treatment and a high mortality rate in hospitalized patients. The objective of this study was to describe and compare the clinical characteristics and the management of patients dying with SARS-CoV-2 infection in the acute medical and intensive care setting.
METHODS
Descriptive analysis of dying patients enrolled in the Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS), a non-interventional cohort study, between March 18 and November 18, 2020. Symptoms, comorbidities and management of patients, including palliative care involvement, were compared between general ward and intensive care unit (ICU) by univariate analysis.
RESULTS
580/4310 (13%) SARS-CoV-2 infected patients died. Among 580 patients 67% were treated on ICU and 33% on a general ward. The spectrum of comorbidities and symptoms was broad with more comorbidities (≥ four comorbidities: 52% versus 25%) and a higher age distribution (>65 years: 98% versus 70%) in patients on the general ward. 69% of patients were in an at least complicated phase at diagnosis of the SARS-CoV-2 infection with a higher proportion of patients in a critical phase or dying the day of diagnosis treated on ICU (36% versus 11%). While most patients admitted to ICU came from home (71%), patients treated on the general ward came likewise from home and nursing home (44% respectively) and were more frequently on palliative care before admission (29% versus 7%). A palliative care team was involved in dying patients in 15%. Personal contacts were limited but more often documented in patients treated on ICU (68% versus 47%).
CONCLUSION
Patients dying with SARS-CoV-2 infection suffer from high symptom burden and often deteriorate early with a demand for ICU treatment. Therefor a demand for palliative care expertise with early involvement seems to exist.

Identifiants

pubmed: 35905129
doi: 10.1371/journal.pone.0271822
pii: PONE-D-21-32351
pmc: PMC9337665
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0271822

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Pain Symptom Manage. 2020 Jul;60(1):e27-e30
pubmed: 32276101
BMC Health Serv Res. 2021 Sep 22;21(1):998
pubmed: 34551766
J Bioeth Inq. 2020 Dec;17(4):777-782
pubmed: 33169271
Infection. 2021 Feb;49(1):63-73
pubmed: 33001409
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Sci Data. 2020 Dec 10;7(1):435
pubmed: 33303746
Am J Hosp Palliat Care. 2021 Feb;38(2):191-198
pubmed: 33021094
Ann Hematol. 2021 Feb;100(2):383-393
pubmed: 33159569
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Viruses. 2020 May 10;12(5):
pubmed: 32397688
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
BMJ Support Palliat Care. 2020 Dec;10(4):381-384
pubmed: 32467101
PLoS One. 2017 Apr 6;12(4):e0175124
pubmed: 28384214
Crit Care Nurs Clin North Am. 2015 Sep;27(3):315-39
pubmed: 26333754
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Infection. 2021 Aug;49(4):725-737
pubmed: 33851328
Int J Infect Dis. 2020 Jun;95:311-315
pubmed: 32234343
Crit Care. 2020 Jul 28;24(1):465
pubmed: 32723347
Cell. 2020 Dec 10;183(6):1735
pubmed: 33306958
MMWR Morb Mortal Wkly Rep. 2020 Jul 17;69(28):923-929
pubmed: 32673298
Intern Med J. 2021 Mar;51(3):433-435
pubmed: 33645873
J Pain Symptom Manage. 2020 Oct;60(4):e2-e13
pubmed: 32721500
Front Med (Lausanne). 2020 Dec 03;7:567296
pubmed: 33344469
Eur Respir J. 2020 Apr 23;55(4):
pubmed: 32269090
J Pain Symptom Manage. 2020 Jul;60(1):e70-e76
pubmed: 32298748
J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1796-1800
pubmed: 32506122

Auteurs

Claudia Raichle (C)

Department of Geriatric and Palliative Medicine, Tropenklinik Paul-Lechler-Krankenhaus, Tübingen, Germany.

Stefan Borgmann (S)

Department of Infectious Diseases and Infection Control, Ingolstadt Hospital, Ingolstadt, Germany.

Claudia Bausewein (C)

Department of Palliative Medicine, LMU Hospital, München, Germany.

Siegbert Rieg (S)

Division of Infectious Diseases, Department of Medicine II, Medical Centre-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Carolin E M Jakob (CEM)

Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Steffen T Simon (ST)

Department of Palliative Medicine, Faculty of Medicine, University of Cologne, Cologne, Germany.

Lukas Tometten (L)

Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Jörg Janne Vehreschild (JJ)

Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Center for Internal Medicine, Medical Department 2, Hematology/Oncology and Infectious Diseases, University Hospital of Frankfurt, Frankfurt, Germany.
German Centre for Infection Research, partner site Bonn-Cologne, Cologne, Germany.

Charlotte Leisse (C)

Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Johanna Erber (J)

Department of Internal Medicine II, University Hospital rechts der Isar, Technical University of Munich, Munich, Germany.

Melanie Stecher (M)

Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
German Centre for Infection Research, partner site Bonn-Cologne, Cologne, Germany.

Berenike Pauli (B)

Department of Palliative Medicine, Faculty of Medicine, University of Cologne, Cologne, Germany.

Maria Madeleine Rüthrich (MM)

Department of Internal Medicine II, Hematology and Medical Oncology, University Hospital Jena, Jena, Germany.

Lisa Pilgram (L)

Center for Internal Medicine, Medical Department 2, Hematology/Oncology and Infectious Diseases, University Hospital of Frankfurt, Frankfurt, Germany.

Frank Hanses (F)

Emergency Department, University Hospital Regensburg, Regensburg, Germany.
Department for Infectious Diseases and Infection Control, University Hospital Regensburg, Regensburg, Germany.

Nora Isberner (N)

Department of Internal Medicine II, Division of Infectious Diseases, University Hospital Würzburg, Würzburg, Germany.

Martin Hower (M)

Department of Internal Medicine, Klinikum Dortmund, Dortmund, Germany.

Christian Degenhardt (C)

Department of Pharmacy, Städtisches Klinikum, Karlsruhe, Germany.

Bernd Hertenstein (B)

Klinikum Bremen-Mitte, Bremen, Germany.

Maria J G T Vehreschild (MJGT)

Department of Internal Medicine 2, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.

Christoph Römmele (C)

Department of Internal Medicine III-Gastroenterology and Infectious Diseases, University Hospital Augsburg, Augsburg, Germany.

Norma Jung (N)

Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH